Lauren Treadwell, MD
Family Medicine · Jackson, MSNPI 1801108196
Payments from drug & device makers
Across 166 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$489
- Novo Nordisk$334
- Lilly USA, LLC$233
- Amgen$215
- Abbott$198
- Astellas Pharma US Inc$168
- plus $977 from 20 others
What the payments were for
- Food & beverage$2,614100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 34 | $489 |
| Novo Nordisk | 22 | $334 |
| Lilly USA, LLC | 15 | $233 |
| Amgen | 14 | $215 |
| Abbott | 10 | $198 |
| Astellas Pharma US Inc | 11 | $168 |
| Boehringer Ingelheim | 11 | $165 |
| GSK | 8 | $146 |
| Pfizer | 8 | $109 |
| Idorsia Pharmaceuticals US Inc | 6 | $90 |
| AstraZeneca | 6 | $83 |
| Bayer | 3 | $56 |
| Shield Therapeutics Inc | 2 | $44 |
| Exact Sciences | 2 | $37 |
| Genentech USA, Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Merck | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Inari Medical, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Gilead | 1 | $17 |
| Medtronic | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
How this compares
$2,614 in reported general payments places this provider in the 75th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $138,647 |
| JanuviaSitagliptin Phosphate | 53 | $64,953 |
| JardianceEmpagliflozin | 40 | $50,912 |
| RybelsusSemaglutide | 34 | $39,736 |
| XareltoRivaroxaban | 26 | $35,820 |
| MyrbetriqMirabegron | 39 | $33,059 |
| MounjaroTirzepatide | 29 | $29,911 |
| EliquisApixaban | 23 | $28,169 |
| TradjentaLinagliptin | 37 | $24,992 |
| LinzessLinaclotide | 15 | $13,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,500 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $4,755 |
| Atorvastatin Calcium | 578 | $4,227 |
| Pregabalin | 66 | $3,635 |
| Humalog Mix 75-25Insulin Lispro Protamin/Lispro | 11 | $3,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $334 | $178,383158 claims |
| Boehringer IngelheimJardiance, Tradjenta | $165 | $75,90477 claims |
| MerckJanuvia | $20 | $64,95353 claims |
| Johnson & JohnsonXarelto | $13 | $35,82026 claims |
| Lilly USA, LLCMounjaro, Humalog Mix 75-25 | $233 | $33,48640 claims |
| Astellas Pharma US IncMyrbetriq | $168 | $33,05939 claims |
| PfizerEliquis | $109 | $28,16923 claims |
| AbbVieLinzess, Synthroid | $489 | $14,82032 claims |
| GSKTrelegy Ellipta | $146 | $11,50018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Jackson
- Alexander OsowaJackson$2.2M
- Andrea PhillipsJackson$268K
- Dava ClevelandJackson$100K
- Massie HeadleyJackson$10K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.